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Abstract
Purpose of Review To review the incidence, treatment and genetics of psychosis in people withmild cognitive impairment (MCI)
and Alzheimer’s disease (AD).
Recent Findings Psychosis in Alzheimer’s disease (AD) has an incidence of ~ 10% per year. There is limited evidence regarding
psychological interventions. Pharmacological management has focused on atypical antipsychotics, balancing modest benefits
with evidence of long-term harms. The 5HT2A inverse agonist pimavanserin appears to confer benefit in PD psychosis with
initial evidence of benefit in AD. Cholinesterase inhibitors give modest benefits in DLB psychosis. The utility of muscarinic
agonists, lithium, glutamatergic and noradrenergic modulators needs further study.
Summary Recent work has confirmed the importance of psychosis in MCI as well as AD. The lack of evidence regarding
psychological therapies is an urgent knowledge gap, but there is encouraging evidence for emerging pharmacological treatments.
Genetics will provide an opportunity for precision medicine and new treatment targets.
Keywords Alzheimer’s disease . Psychosis . Frequency . Impact . Mechanisms . Non-pharmacological . Pharmacological
Introduction
Psychosis occurs in the majority of people with Alzheimer’s
disease over the course of their illness. It is distressing for
patients and caregivers and is associated with an accelerated
trajectory of decline and dependency. Recent work has fo-
cussed on the presence of psychosis in people with mild cog-
nitive impairment (MCI), as a risk factor for the development
of Alzheimer’s disease. Over the last few years, studies have
also begun to identify novel risk factors, and there have been




There are 45 million people with dementia worldwide, the
majority of whom have Alzheimer’s disease (AD) [1]. While
AD is commonly thought of as a memory disorder, behaviour-
al and psychological symptoms of dementia (BPSD) are near-
ly universal and include psychotic symptoms. Over half of
people with AD will experience psychotic symptoms during
their illness [2, 3]. Systematic reviews indicate a cross-
sectional prevalence of about 40%, though lower rates in com-
munity populations and higher rates in clinical settings are
recognized. Notably, most prevalence studies reflect popula-
tions with a mean MMSE indicating moderate AD severity
[3–6]. Subsequent work has confirmed a lower frequency of
psychosis in mild AD, with one US study of over 6000 people
reporting a prevalence of 12% for delusions and 3% for
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hallucinations [7]. Subsequent studies evaluating psychosis in
mild cognitive impairment (MCI) demonstrate a prevalence
higher than age-matched controls and lower than people with
AD [8]. The two largest studies suggest a 3–5% frequency of
delusions and 1% hallucinations in MCI [7, 9]. Sub-
syndromal delusions and hallucinations are also present in
cognitively normal older adults, at a frequency of around 3%
and less than 1% respectively, and may represent early marker
cognitive decline [10, 11•].
In dementia, once present, psychotic symptoms commonly
persist for at least a year in two-thirds of people [12]. A
follow-up study reported a 2-year persistence of delusions
and hallucinations in 43% and 73% of people, respectively
[2]. However, this may conceal an underlying pattern of re-
mission and recurrence. For example, in 125 people with AD
followed monthly for 12 months, 30 (54%) had resolution of
symptoms over 3 months without specific treatment, but
among these, eight (27%) subsequently relapsed in the first
year [13]. Over the last 15 years, studies have consistently
highlighted the impact of psychotic symptoms in MCI,
predicting greater cognitive decline and more rapid conver-
sion to AD or other dementias [14–16].
Definition and Diagnosis
Psychosis is defined by the presence of delusions, delusional
misidentification and hallucinations. Although, superficially,
this suggests similarity to functional psychotic disorders such
as schizophrenia, the phenomenology of psychosis in dementia
is very different. Delusions, present in around 35% of people,
are usually simple; common symptoms include delusions of
theft, persecution, infidelity, abandonment or that deceased rel-
atives are still living [17, 18]. Other delusions in AD are related
to misidentification such as beliefs that one’s home is not one’s
home; that a family member is someone else, has been dupli-
cated or is an imposter (Capgras delusion); or that someone is
living in the house (phantom boarder delusion) [19]. Evenmore
common symptoms include misperceiving television, mirror or
photographic images as real people or objects.
Hallucinations are one of the most frequent psychotic symp-
toms in AD with a median prevalence of 23% across studies
[14]. Hallucinations can occur in any sensory modality, but
visual hallucinations are the most frequent, followed by audito-
ry [4]. Typical hallucinatory symptoms of schizophrenia such
as hearing multiple voices talking to one another or running a
commentary on the person’s actions are extremely rare in AD.
The most widely used diagnostic criteria are those pro-
posed by Jeste and Finkel [4]. In addition to the presence of
psychotic symptoms, the criteria require clarification that the
psychotic symptoms are not part of a delirium or functional
psychosis and did not pre-date AD onset. Symptoms should
also have been present for at least a month and result in func-
tional disability on the individual or others.
Diagnostic criteria and many clinical trials consider psy-
chosis as a unitary syndrome, but there is evidence highlight-
ing different genetic and neurochemical associations with hal-
lucinations and delusions, respectively (discussed below).
Research further suggests differences between individuals
with delusions who do or do not have concurrent agitation
[20]. People with agitation often have more persistent symp-
toms and a better response to therapies (see treatment section),
although it is unclear whether this is a different group phe-
nomenologically or whether the agitation is a marker of great-
er severity. Literature suggests that people with delusions who
do not have agitation are more likely to also have
hallucinations.
There is increasing evidence that the presence of mild be-
havioural impairment (MBI), which includes psychosis, is a
risk factor for and possibly a prodrome to AD [11•, 21]. In this
context, exclusion of psychosis pre-dating dementia may be
unhelpful, particularly for case/control research studies where
false negatives should be minimized, although it remains im-
portant to exclude individuals with longstanding functional
psychoses throughout adulthood. Accordingly, new criteria
reflecting this are being proposed by the Alzheimer’s
Association International Society to Advance Alzheimer’s
Research and Treatment (ISTAART).
Impact and Outcomes of Psychosis
Psychotic symptoms are frequently distressing to the individ-
ual and their caregivers and associated with poorer disease
outcomes [22]. In a landmark study, Stern et al. reported that
psychosis was associated with more rapid cognitive decline
[23]. A review of 55 studies examining AD with psychosis
found that 20 of 30 studies with cross-sectional assessments
found greater cognitive impairment in ADwith psychosis than
without [17]. It highlighted that all 9 studies evaluating the
link between psychosis and cognitive decline supported the
initial observation of more progressive cognitive impairment
in the presence of psychosis. More recent studies have con-
firmed this association and shown similar impact in MCI
[14–16, 24]. Importantly, the association between AD psycho-
sis and cognitive decline does not appear attributable to other
factors including age, age of AD onset, AD duration, sex, race,
education and family psychiatric history [17]. Notably, several
studies have suggested that among people who develop psy-
chosis, there is a sharper trajectory of decline even prior to the
onset of frank psychotic symptoms, with one study finding
that more rapid cognitive decline was present a year before
the development of psychosis [16, 25, 26]. This consistent and
building evidence suggests that there may be a different un-
derlying biological and/or genetic predisposition in these
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individuals, and the presence of psychosis represents a more
severe AD phenotype [27].
Psychosis is also associated with more rapid progression of
functional impairment, hospital admissions, earlier admission
to institutional care and increased mortality [14, 16, 24, 28,
29]. It has also been reported that initial psychosis is associat-
ed with increased subsequent dependency, independent of
cognitive decline. In addition, psychotic symptoms are often
antecedent to or comorbid with other neuropsychiatric symp-
toms like agitation, aggression and depression, further adding
to the impact on the individual and others [20, 30].
Genetic Correlates
The observation, replicated across studies and cohorts, that the
risk for psychosis in AD runs in families, with an estimated
heritability of 61% (which compares with 81% for schizophrenia
and 50–60% for AD itself), provides compelling evidence that
AD psychosis may be strongly influenced by genetic variation
[30–36]. To date, only one small genome-wide association study
(GWAS) of psychosis in AD has been reported, and no single
nucleotide polymorphism (SNP) demonstrated genome-wide
significance, although evidence suggested an association with
an aggregated genetic risk score comprising multiple loci [37].
A follow-up study provided independent replication of a poly-
genic association of common variants with AD psychosis, al-
though no individual SNP reached genome-wide significance
[38]. The strongest associations were with three SNPs within
the antisense transcript, RP11-541P9.3, a likely regulator of
CCNG1 expression. CCNG1 may act to inhibit tau phosphory-
lation by cyclin-dependent kinases [39, 40]. This study found
that polygenic risk for schizophrenia was protective against psy-
chosis risk in AD, although opposing findings exist which im-
plicate genetic liability of schizophrenia [41]. It should be noted
that neither study nor the majority of candidate gene association
studies have found psychosis risk to be influenced by APOE4
genotype [42].
Another small GWAS of structural copy number variants
(CNV) with AD psychosis has been reported [43]. Although
total CNV burden did not differ between AD cases with and
without psychosis, a duplication in the APC2 gene demon-
strated genome-wide significant association with AD psycho-
sis (OR = 0.42; P = 7.2 × 10–10) [42]. CNVs in three other
genes, SET, JAG2, and ZFPM1, suggested association with
AD psychosis risk. While intriguing, all of these findings re-
quire replication in larger cohorts, and it is important to note
that all have been conducted in cohorts of European ancestry,
so findings are not generalizable to other populations. To date,
no study has reported an association from exome or whole
genome sequencing with AD psychosis, but these approaches
will be required for the detection of rare, highly penetrant
variants which confer risk or protection.
Neurobiological Underpinnings
There is an urgent need for effective treatments to manage
psychotic symptoms in AD, but there remain no licenced ther-
apies. A rational approach to therapy requires better under-
standing of potential neurobiological mechanisms. Key pos-
tulated neural mechanisms of AD psychosis that represent
potential treatment targets include the following: (1) dopa-
mine D3 receptors, (2) serotonin (5HT), (3) cholinergic mus-
carinic receptors, (4) tau protein and (5) kalirin.
Dopamine D2/3 Receptors
Post-mortemwork has indicated a relationship between higher
dopamine D3 receptor density in the nucleus accumbens and
AD psychosis [44]. These findings are supported by a PET
study using [11C] raclopride, in 21 people with AD, which
highlighted significantly higher striatal D2/D3 receptor avail-
ability in AD patients with delusions compared with those
without [45]. It is perhaps noteworthy that the last published
major GWAS of schizophrenia (in 36,989 cases and 113,075
controls) implicated the dopamine receptor 2 (DRD2) gene
[46]. Although it is important to interpret candidate gene stud-
ies cautiously, and not every study confirms an association,
the balance of evidence suggests a link between D3 polymor-
phisms and increased risk of AD psychosis, although this will
need to be re-evaluated in the context of emerging GWAS
studies [42]. Some current atypical antipsychotics, such as
aripiprazole, have increased D3 potency, and interestingly
aripiprazole is the only historical atypical antipsychotic to
demonstrate significant benefit in the treatment of AD psycho-
sis in a single RCT [47]. Attempts have been made to develop
more selective D3 antagonists (e.g. S33138, RG15,
cariprazine), but none have progressed to clinical trials in
AD psychosis.
Serotonin (5HT)
A series of post-mortem reports have suggested a reduction in
serotonin (5-HT) in the ventral temporal cortex and
prosubiculum in AD psychosis compared with AD without
these symptoms [48–50]. Other post-mortem studies indicated
lower cell counts in dorsal raphe nucleus in AD patients with
psychosis, potentially explaining the reduced 5HT [51]. A
2009 review highlighted that 6 of 9 studies examining
5HT2A polymorphisms reported a significant association
with psychosis, but not with agitation/aggression or depres-
sion [52]. This evidence will need to be reviewed as additional
GWAS studies emerge. With emerging ligands, there are op-
portunities to build on this work with PET studies. Of note,
genetic polymorphism studies highlight a similar relationship
between psychosis and 5 T polymorphisms in dementia with
Lewy bodies (DLB) [53].
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Cholinergic Muscarinic Receptors
Psychosis in AD has been associated with higher muscarinic
M2 receptor density in orbitofrontal gyrus and temporal asso-
ciation cortex than AD patients without psychosis [54]. Other
post-mortem work has suggested loss of [3H]4-DAMP bind-
ing (a ligand to M1, M3, M4 and M5 receptors) in AD psy-
chosis, contrasting with work in DLB which reported that
delusions are associated with upregulation of M1 receptors
[55, 56]. Post-mortem studies have consistently suggested a
link between psychosis and an altered monoamine-cholinergic
balance in both AD and DLB [49, 57]. Overall there is strong
evidence linking changes in muscarinic receptors in AD and
DLB, and further refinement is needed to understand the op-
timal treatment targets.
Tau
Tau pathology is one of the most widely studied neurological
correlates of AD psychosis. A number of studies have shown
it to be associated with increased neurofibrillary tangle density
and concentrations of phosphorylated tau in the neocortex,
frontal cortex and CSF relative to AD without psychosis
[58–61]. There is also work suggesting that the frequency of
psychosis and persistence of psychotic symptoms are greater
in AD patients with the extended MAPT tau haplotype [62].
On balance, this supports the potential utility of anti-tau
agents, particularly for psychosis, of which there are a number
in development for AD itself.
Kalirin
Kalirin, a rho guanine nucleotide exchange factor, involved in
dendritic spine growth has been implicated in schizophrenia.
Recent studies have shown that reductions in kalirin are asso-
ciated with improvements in psychosis-associated behaviours
in AD mouse models, supporting earlier findings in post-
mortem tissue [63, 64•]. Notwithstanding the challenges and
complexities of assessing the AD psychosis phenotype in an-
imal models, these findings indicate novel pathways, such as
synaptic resilience, which warrant further investigation [65].
They also highlight the value of preclinical testing in identi-
fying such mechanisms.
Potential Factors Exacerbating Psychosis
in AD
Individuals with Dementia Factors
Factors that may exacerbate AD psychosis include acute med-
ical conditions (e.g. pain, infection, dehydration), medication
side effects or drug-drug interactions, unmet needs (e.g. fear,
lack of sleep, boredom) and pre-existing psychiatric illness
(e.g. bipolar disorder, schizophrenia) [66].
Caregiver Factors
There is ample evidence that BPSD-like psychosis may be
triggered or exacerbated when a caregiver is stressed or de-
pressed. Other caregiver factors that may worsen psychosis
include negative communication styles (e.g. anger, screaming,
negative affect), critical management styles and mismatch of
caregiver expectations with the stage of illness [67].
Environmental Factors
Stress may be caused by changes in routine, too many com-
peting or misleading stimuli, lack of stimuli, physical and
environmental challenges and demands that exceed functional
ability [68••].
Current and Future Approaches for Treating
Psychosis
Best practice guidelines, including a recent international con-
sensus panel, emphasize the importance of investigating and
treating underlying causes such as delirium, drugs increasing
psychosis risk and sensory impairments [68••]. New opera-
tionalized approaches such as DICE (DESCRIBE-
INVESTIGATE-CREATE-EVALUATE) [69] incorporate
this into a framework enabling more consistent implementa-
tion in clinical practice. Potential underlying causes are
outlined in Fig. 1.
Recently published consensus outcomes from a Delphi
panel support an escalating approach to the clinical manage-
ment of AD psychosis [68••]. This should start with a thor-
ough investigation of underlying causes—which for psycho-
sis may be delirium resulting from an untreated infection for
example—and psychotropic management commenced only
after consideration of other potential causes.
Second-line treatment with risperidone has been recom-
mended. Other antipsychotics such as aripiprazole,
olanzapine, quetiapine and haloperidol were not considered
to have sufficient published evidence to be included in the
final consensus.
Non-pharmacological Treatments
Although there is a substantial literature to support the benefits
of non-pharmacological interventions in the treatment of agi-
tation and aggression [68••, 70], there is no RCT evidence to
support the value of specific psychological or other non-
pharmacolog ica l the rap ies fo r peop le wi th AD
psychosis[68••]. Over the last 20 years, there have been
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advances in various non-pharmacological therapies for psy-
chosis in schizophrenia and affective disorders. These include
cognitive behavioural therapy and innovative approaches
combining psychological therapy with technology (e.g. virtual
reality) [71]. There has beenminimal work to adapt this or AD
psychosis, although a small series reporting CBT intervention
in dementia patients experiencing psychotic symptoms sug-
gested potential benefit [72].
Various cohort studies also demonstrate a relationship be-
tween visual hallucinations in AD and either impaired visual
acuity or eye pathologies such as cataracts [72]. One study
reported resolution of visual hallucinations in a small group
following cataract surgery, suggesting an opportunity to im-
prove the current treatment pathway [73].
Pharmacological Treatments
While preclinical drug development has been limited, there
has been a recent increase in RCTs of repurposed and novel
agents, but less in AD psychosis than agitation. Current
clinical compounds and those at various stages of clinical
development for AD psychosis are reviewed below.
Atypical Antipsychotics
Atypical antipsychotics are the most widely used pharmaco-
logical treatment for AD psychosis. Other than pimavanserin
which has a more specific mechanism of action and is
reviewed in the next section, there have been no new RCTs
of atypical antipsychotics in AD psychosis over the last
6 years, and the evidence has been thoroughly reviewed in
previous articles [74]. A meta-analysis discussed seven trials
reporting psychosis as an outcome [75]. When combined, the
data from three trials with risperidone demonstrated a modest
but significant improvement compared with placebo at a dos-
age of 1 mg per day but not at higher or lower doses (− 0.8
point in BEHAVE-AD, standardized effect size Cohen’s d <
0.2). Two olanzapine trials showed a nonsignificant trend to-
wards benefit. The only other antipsychotic to demonstrate
some significant benefit in an RCT is aripiprazole, in a care
setting of over 400 people [47]. Risperidone is licenced in the
Fig. 1 Conceptual model of psychosis in AD
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EU, but not in the USA, for the short-term treatment of ag-
gression in AD, but not psychosis. The modest benefits of
antipsychotics in the treatment of AD psychosis need to be
balanced against the substantial burden of adverse events.
The severe adverse events associated with atypical antipsy-
chotics in AD psychosis are well established and include in-
creased risk of parkinsonism, oedema, falls, deep vein thrombo-
sis, pneumonia, stroke and a near 2-fold increased risk of mor-
tality [76–79]. These side effects resulted in FDA issuing a black
boxwarning on the use of antipsychotics in peoplewith dementia
and for similar warnings by regulatory authorities in Europe.
Emerging Pharmacological Treatments
Recent years have seen a small but encouraging increase in the
number of compounds in trials. The recent Delphi consensus
highlighted pimavanserin and citalopram as the most promis-
ing potential therapies [68••].
Pimavanserin
Pimavanserin is a novel antipsychotic with a highly selective
5HT2A mechanism of action, lacking dopaminergic, cholinergic
or histaminergic activity. Pimavanserin confers benefit in the
treatment of PD psychosis and is licenced for this indication in
the USA [80]. Phase II trial results of 181 patients with AD
psychosis were recently published showing 55% of patients in
the treatment arm experienced symptom improvement at the 6-
week primary endpoint (compared with 37% in the placebo
group). The adjusted mean difference for this primary outcome
was − 1.84 in favour of pimavanserin, with a Cohen’s d standard-
ized effect size of 0.32 comparing favourably with the 0.2 stan-
dardized effect size emerging from meta-analyses of RCTs of
atypical antipsychotics [81•]. A subgroup analysis suggested that
pimavanserin conferred greater benefit in peoplewithmore severe
symptoms, with an adjusted mean difference of − 4.43 favouring
pimavanserin (standardized effect size 0.73) in people with a
combined delusions/hallucinations NPI score of ≥ 12. Caution
should be exercised interpreting this exploratory analysis; howev-
er, it is an interesting finding as this more severe group is in most
in need of effective treatment, and this level of benefit would
clearly be clinically meaningful if confirmed in a further trial.
An exploratory analysis also suggested that participants
with concurrent agitation who received pimavanserin together
with a concomitant SSRI showed improved efficacy com-
pared with those taking pimavanserin alone [81•]. This has
to be interpreted cautiously as this was an exploratory analy-
sis. However, it is consistent with previous data in PD psy-
chosis [80], suggesting the possibility of added benefit which
merits further evaluation. It is worth noting that the combina-
tion may lead to QTcF prolongation.
It is also important to note that the sustained effect of
pimavanserin was unclear as there was no benefit over placebo
at 12 weeks.Whether this represents an attenuation of treatment
effect or a reflection of the recurring-relapsing course of symp-
toms remains to be established. A phase III relapse prevention
trial of pimavanserin with a longer follow-up period is now
underway and may address these issues.
The phase II trial also evaluated safety. QTcF prolongation
(< 10 ms with no associated adverse events) was observed in
the treatment group. This is consistent with the caution in the
current US label for pimavanserin in PD. In contrast to other
antipsychotic drugs, there were no increases in sedation, par-
kinsonism, stroke, accelerated cognitive decline,
haematologic disorder, cardiovascular events or other signifi-
cant safety risks including sudden death, . In this study, there
were 4 deaths in the pimavanserin group and 4 in placebo.
A phase 3 study of pimavanserin has recently been completed
using a relapse prevention design, and incorporating participants
with AD, DLB/PDD, vascular dementia and fronto-temporal
dementia has recently been completed. Participants received a
2 week non-pharmacological intervention, with non-responders
progressing to 12 weeks of open-label treatment with
pimavanserin. One hundred ninety-four (62%) of participants
with a significant treatment response progressed to a double-
blind withdrawal phase over 6 months, where participants were
randomized to continue pimavanserin or to placebo. Over the
6 months of the double-blind phase, there was a 65% highly
significant reduction in relapse among participants receiving
pimavanserin, with a good tolerability profile and only 1 death
in the group receiving pimavanserin. So far these results have
only been published in abstract linked to a conference presenta-
tion (https://www.neurologylive.com/clinical-focus/in-dementia-
pimavanserin-significantly-reduces-psychosis-relapse), and we
await the full publication of the results.
Although pimavanserin remains investigational for AD
psychosis, it is licenced in the USA for PD psychosis.
Similar to other antipsychotic drugs, pimavanserin received
a black box warning for mortality risk when it was approved
by FDA. In recent media reports, its safety in PD psychosis
has come under scrutiny due to a perceived increase in death
rate. These include a CNN report citing 700 deaths registered
in FDA’s adverse event reporting system (FAERS) as well as
a report from the Institute of Safe Medical Practices (ISMP)
that identified 244 deaths during the first 6 months after ap-
proval. It is difficult to draw conclusions from these databases,
given that these are spontaneous reports and the inherent lack
of control over how events are reported. Based on the avail-
able safety data, the FDA has recently concluded that there are




Another important consideration is the potential increased
mortality risk when pimavanserin is prescribed in conjunction
with an atypical antipsychotic. The only published data
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addressing this is a long-term open-label safety study in PD psy-
chosis [82]. In this study, 66 participants had other antipsychotics
added to their regimen, and the safety profile was retrospectively
compared with the 357 who remained on pimavanserin alone.
There were 18.8 deaths per 100 patient-years in the group who
added another antipsychotic compared with 4.5 deaths per 100
patient-years in those who remained on pimavanserin alone. In
addition, there was almost a threefold increase in serious
treatment-emergent adverse events in the group receiving an atyp-
ical antipsychotic. The combination of pimavanserin and an atyp-
ical antipsychotic is therefore an important issue for PD psychosis
patients butmay also be an issue for patientswithADpsychosis if
pimavanserin is licenced for this indication.
Citalopram
The CITAD trial randomized 186 people with AD to citalopram
(ascending to 30 mg per day) or placebo for 9 weeks, demon-
strating benefits in the primary outcome for agitation [83]. More
recently, an analysis of secondary outcomes suggested benefits in
both delusions and hallucinations in participants receiving
citalopram compared with those receiving placebo, with the best
response in individuals with psychosis and agitation [84].
Although this is a secondary outcome, it merits further study.
A sub-study examining the genetic associations of treatment re-
sponse showed a link between both HTR2A and HTR2C recep-
tor polymorphisms and response to citalopram, suggesting a
mechanistic link for the treatment of agitation, but no such eval-
uation was undertaken for psychosis.
New Atypical Antipsychotics
ITI-007 (lumateperone) and SUVN-M8036 are two novel an-
tipsychotics with 5HT2A and D2 modulation properties.
Phase III trials of ITI-007 for schizophrenia, bipolar depres-
sion (NCT03817528) and agitation in AD (NCT03249376)
are underway, and a future focus on AD psychosis is possible.
A key unanswered question is whether clozapine is effective
for AD psychosis. There are no RCTs or substantive open trials
of clozapine in AD. Two small RCTs in people with PD psy-
chosis suggested meaningful efficacy, but in the context of well-
established safety concerns such as neutropenia and mortality
[85, 86].
Anti-dementia Drugs
There is consistent evidence across clinical trials that both
cholinesterase inhibitors and memantine may have a modest
but significant impact on the overall level of neuropsychiatric
symptoms. Although secondary exploratory analyses have
suggested potential benefit in the treatment or reduced emer-
gence of psychosis in AD with donepezil and memantine,
there is no direct RCT evidence indicating a specific benefit
in the treatment of clinically significant AD psychosis [87,
88]. There is evidence that cholinesterase inhibitors confer




MP-101 is a novel metabotropic glutamate receptor type 2
(mGluR2) and 3 (mGluR3) agonist currently being evaluated
in a phase II trial (NCT03044249) for the treatment of
dementia-related psychosis, with results expected in 2021
(https://clinicaltrials.gov/ct2/show/NCT03044249). MP-101
was originally developed for bipolar disorder, but this pro-
gramme was discontinued in 2016.
Lithium
The Lit-AD study is the first RCT of lithium for AD neuropsy-
chiatric symptoms (NCT02129348). It primarily focuses on ag-
itation but also examines agitation with and without psychosis,
the rationale being that lithium has long been used as a therapy
for other psychotic disorders in the context of bipolar disease. A
small series of investigator-led case reports suggested benefit on
psychosis; however, this was an exploratory analysis, so it will
require a more robust evaluation for AD psychosis [90].
Muscarinic Agonists
As discussed above, post-mortem studies suggest that changes in
M1 and M2 receptors are potentially associated with psychosis
(particularly delusions) in AD and other dementias. A 1997 RCT
of xanomeline with a primary outcome of cognition showed a
highly significant beneficial effect on psychotic symptoms; how-
ever, there was an unacceptably high discontinuation rate (>
50%, largely due to GI side effects) in the active arm [91].
However, there remains interest in using muscarinic agents for
cognition. Recently, a phase I pilot tolerability study evaluating
xanomeline in combination with trospium chloride showed a
46% reduction in cholinergic side effects (NCT02831231).
Given the previous AD efficacy data, this novel combination
may represent a step towards re-evaluating the role of
xanomeline in AD. There are now also novel muscarinic com-
pounds in the development pipeline for AD and DLB.
Conclusion
It is encouraging to see an improving understanding of potential
mechanisms underlying psychosis in people with AD and a re-
lated increase in the number and breadth of intervention studies.
Further genetic studies will be critical to identify novel treatment
Curr Neurol Neurosci Rep           (2020) 20:57 Page 7 of 10    57 
targets and to develop a framework for effective precision
medicine.
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